In this brief report, the authors discuss evidence for intramuscular use of haloperidol with lorazepam and diphenhydramine, also known as intramuscular B52, in aggressive patients.
Incidents involving both a homicide and a suicide are rare and vary widely in terms of motive and circumstances. Read this study to learn about 8 classifications of homicide-suicides the authors developed using a large database.
Here, read about a 29-year-old woman who presented to our inpatient psychiatric facility for manic-like symptoms including pressured speech, flight of ideas, sexual preoccupations, and self-reported euphoria.
Intermittent explosive disorder (IED) is associated with intimate partner assault, the use of weapons to threaten others, and arrests. This behavior can be reduced through pharmacologic and psychosocial interventions. Learn about IED in this CME journal article.
Daily partner violence often occurs irregularly, making violence unpredictable. But the degree of unpredictability is a strong predictor of patient outcomes. Here, read about a 10-item scale designed to simplify assessment of violence irregularity.
Given the limited efficacy and questionable safety profiles of current pharmacologic treatments of agitation in Alzheimer's disease (AD), the therapeutic potential of natural and synthetic cannabinoids are being explored in AD-related agitation. This meta-analysis reviews the efficacy and safety of these treatments.
Treatment-resistant aggressive behavior is commonly observed in psychiatric patients with psychosis, especially in state mental health institutions and prison systems with high health care and societal costs. Could dextromethorphan/quinidine be a potentially safe and tolerable alternative to conventional treatment regimens for treatment-resistant aggression and impulsive behavior in these patients? Read this retrospective case study to find out more.
Although some studies suggest that excessive brain opioid activity may affect or even determine the pathogenesis of autism, discrepancies exist between results of individual studies. Read this article to learn if a relationship was found between β-endorphin levels, self-injurious behaviors, or pain reactivity in patients with autism.
Childhood abuse is associated with suicidal ideation. Although factors predicting disclosure of child abuse have been examined, to date, few studies have examined the impact of disclosure of child abuse to child protection services on life-threatening behaviors such as suicidal ideation. The authors of this study examined the proportion of Canadian adults with a history of child abuse who disclosed the abuse to child protection services before age 16 years and the effect of that disclosure on lifetime suicidal ideation. Read on to find out more.
About 86% of the current US military force is male, and intimate partner violence among military veterans is a serious public health concern. This RCT is the first to compare treatment as usual with the Strength at Home Men's Program, a trauma-informed group intervention based on a social information processing model. See which worked better.
Suicide and pollen levels have been linked in some prior research, yet no studies have actually examined the relationship between pollen levels and non-fatal self-directed violence. For the first time, a study looks at this intriguing association.
How do you determine what is "normal" teen behavior? Check out this nationwide study of Japanese adolescents to find out which lifestyle factors correlate with intense anger and impulsivity and may help screen for psychiatric disorders.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT